Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate-specific antigen: update 1997.

D W Chan1, L J Sokoll

  • 1Clinical Chemistry Division, Johns Hopkins Medical Institutions, Baltimore, MD, USA.

Journal of the International Federation of Clinical Chemistry
|August 5, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance.

Prostate cancer and prostatic diseases·2017
Same author

Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice.

Prostate cancer and prostatic diseases·2017
Same author

DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-β/SMAD4 signaling.

Oncogene·2016
Same author

Implicit Theory Of Psychopathology.

Multivariate behavioral research·2016
Same author

The interaction between C35 and ΔNp73 promotes chemo-resistance in ovarian cancer cells.

British journal of cancer·2013
Same author

Prostate involvement during sexually transmitted infections as measured by prostate-specific antigen concentration.

British journal of cancer·2011
Same journal

The significance of the International Normalized Ratio (INR) for oral anticoagulant therapy.

Journal of the International Federation of Clinical Chemistry·2010
Same journal

Magnetic resonance spectroscopy in clinical chemistry: the present and the future.

Journal of the International Federation of Clinical Chemistry·1998
Same journal

Aging and oxidative stress.

Journal of the International Federation of Clinical Chemistry·1998
Same journal

Use of antioxidants in the prevention and treatment of disease.

Journal of the International Federation of Clinical Chemistry·1998
Same journal

What is the most accurate, cost-effective way to diagnose acute viral hepatitis?

Journal of the International Federation of Clinical Chemistry·1998
Same journal

Monoclonal gammapathies.

Journal of the International Federation of Clinical Chemistry·1997
See all related articles

Measuring the ratio of free to total prostate-specific antigen (PSA) improves prostate cancer diagnosis. This approach helps differentiate between prostate cancer and benign prostatic hyperplasia (BPH), reducing unnecessary biopsies.

Area of Science:

  • Urology
  • Oncology
  • Biochemistry

Background:

  • Prostate-specific antigen (PSA) is a key tumor marker for prostate cancer but lacks specificity.
  • PSA exists in serum as free and complexed forms, measured by immunoassays with variable results.
  • Differences in assay reactivity to PSA forms affect accuracy.

Purpose of the Study:

  • To enhance the sensitivity and specificity of PSA assays for prostate cancer detection.
  • To evaluate the utility of PSA molecular forms in improving diagnostic accuracy.
  • To reduce unnecessary prostate biopsies in the diagnostic gray zone.

Main Methods:

  • Analysis of free and complexed PSA molecular forms in serum.
  • Measurement of the free to total PSA ratio.

Related Experiment Videos

  • Comparison of PSA forms in patients with and without prostate cancer.
  • Evaluation of PSA ratio's impact on biopsy decisions in the 4-10 μg/L total PSA range.

    • Main Results:

    • Patients with prostate cancer exhibit a higher percentage of PSA complexed with alpha1-antichymotrypsin (ACT).
    • The free to total PSA ratio can reduce unnecessary biopsies by 16-79% in the diagnostic gray zone.
    • Free to total PSA cutoffs are influenced by assay sensitivity, specificity, PSA levels, age, and prostate size.

    Conclusions:

    • Utilizing PSA molecular forms, particularly the free to total ratio, significantly improves diagnostic accuracy for prostate cancer.
    • This method aids in distinguishing prostate cancer from benign prostatic hyperplasia (BPH), thereby reducing unnecessary invasive procedures.
    • Further optimization of PSA measurements involves considering age-specific ranges, PSA velocity, PSA density, and predictive models.